diabetestalk.net

Closed-Loop Insulin Pump Brightens Future Of Diabetes Management

Closed-Loop Insulin Pump Brightens Future of Diabetes Management

Closed-Loop Insulin Pump Brightens Future of Diabetes Management


Closed-Loop Insulin Pump Brightens Future of Diabetes Management
This story is part ofMD Magazine's Year-End Recap series.
Click here for Part 1 , a look into the success of ketamine as a multifaceted therapy.
Click here for Part 2 , a look at the future of Alzheimer's Disease therapies.
For patients with type 1 diabetes (T1D), one of the biggest burdens of the condition is the need to manage it - more specifically, to manage their blood glucose levels .
With the September 2016 approval of the MiniMed670GInsulin Pump System by the US Food and Drug Administration (FDA), produced by Medtronic, the patients ability to manage their glucose became much easier.
Normally, patients with T1D need to monitor their continuous glucose monitoring sensor and use the information the sensor provides them to predict and adjust the dose of insulin they set their pump toadminister. While that open loop system is a major improvement from the previously used multiple daily injections, it still puts a burden on the patient, especially at night and for pediatric patients.
Medtronics device, however, is the first of its kind featuring a closed loop system that self-adjusts to the individual wearer. This allows for real-time alterations in insulin based on the needs at the time, and it is currently the only such device on the market that is able to control dosing automatically. Now, the system does the work for the patient.
Our previous approach with the old pump systems, with set basal rates of insulin infusion that change every couple hours at most, was very nave and inadequate, Kevin P Continue reading

Rate this article
Total 1 ratings
Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Abstract
Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) has already been proven an efficient treatment option for type 2 diabetes. This combination can effectively improve glycated hemoglobin levels, cause weight loss and reduce the dosage of insulin. In addition, it can also reduce the risk of hypoglycemia. Several randomized controlled trials have confirmed that this treatment may be just as effective for type 1 diabetes mellitus (T1DM) patients. The objective of this meta-analysis was to assess the effects and efficacy of the treatment on glycemic changes, weight loss and insulin dosage in type 1 diabetes mellitus patients.
We searched Embase, PubMed and Cochrane for randomized controlled trials (no time restrictions) that investigated combined insulin and GLP-1 treatment. The main endpoints were measurements of glycated hemoglobin and changes in the weight and the dosage of insulin.
In total, 1093 were studies identified, and 7 studies were included in our meta-analysis. GLP-1 agonist and insulin combination therapy led to greater reductions in HbA1c levels [P = 0.03; mean difference −0.21; 95% confidence intervals (CI) (−0.40, 0.02)] and weight [P < 0.05; −3.53 (−4.86, 2.19)] compared to control treatments. The combination therapy did not significantly influence the daily weight-adjusted total insulin dose [P = 0.05; −0.11 (−0.23, 0)], but it did reduce the daily weight-adjusted bolus insulin dose [P = 0.001; −0.06 (−0.1, 0.02)].
Our meta-analysis supports the use of a combined therapeutic regimen of insulin an Continue reading

The use of animal models in diabetes research

The use of animal models in diabetes research


The use of animal models in diabetes research
Diabetes Research Group, King's College London, London, UK
Aileen King, Diabetes Research Group, Guy's Campus, King's College London, London SE1 1UL, UK. E-mail: [email protected]
Received 2011 Aug 19; Revised 2012 Feb 10; Accepted 2012 Feb 13.
Copyright 2012 The Author. British Journal of Pharmacology 2012 The British Pharmacological Society
This article has been cited by other articles in PMC.
Diabetes is a disease characterized by a relative or absolute lack of insulin, leading to hyperglycaemia. There are two main types of diabetes: type 1 diabetes and type 2 diabetes. Type 1 diabetes is due to an autoimmune destruction of the insulin-producing pancreatic beta cells, and type 2 diabetes is caused by insulin resistance coupled by a failure of the beta cell to compensate. Animal models for type 1 diabetes range from animals with spontaneously developing autoimmune diabetes to chemical ablation of the pancreatic beta cells. Type 2 diabetes is modelled in both obese and non-obese animal models with varying degrees of insulin resistance and beta cell failure. This review outlines some of the models currently used in diabetes research. In addition, the use of transgenic and knock-out mouse models is discussed. Ideally, more than one animal model should be used to represent the diversity seen in human diabetic patients.
This paper is the latest in a series of publications on the use of animal models in pharmacology research. Readers might be interested in the previous papers.
Robinson V (2009). Less is more: reducin Continue reading

Most People with Diabetes Should Stop Iron Supplements

Most People with Diabetes Should Stop Iron Supplements


February 16, 2017 by David Mendosa
When you have too much iron in your blood or stored elsewhere in your body might be why your blood glucose level is above normal. In fact, too much iron can even be why you got diabetes. Yet about one out of every five Americans regularly takes an iron supplement.
For years researchers have suspected that when your body accumulates too much iron you are at risk of a host of diseases, according to Berkeley Wellness . In addition to diabetes, iron overload is linked to colorectal cancer, high blood pressure, and hardening of the arteries, as well as to strokes, Alzheimers Disease, and Parkinsons disease.
But only now do we have studies demonstrating the connection between excess iron and diabetes.
Even mildly elevated body iron contributes to the prevalence and incidence of type 2 diabetes, states the news release from the University of Eastern Finland announcing the publication of these studies.
One of these recent studies looked at why men are more likely to have diabetes than women. The International Diabetes Federation estimated that 215.2 million men and 199.5 million women a difference of more than 15 million people had diabetes worldwide in 2015.
Only the abstract of this study, Gender difference in type 2 diabetes and the role of body iron stores , is free online. But the lead author, Alex Aregbesola, M.D., Ph.D., emailed me the full text upon my request. Dr. Aregbesola is a researcher at the Institute of Public Health and Clinical Nutrition, University of Eastern Finland. This study, which includes a prospectiv Continue reading

Type 2 Diabetes: Why Sleep Quality Matters

Type 2 Diabetes: Why Sleep Quality Matters


Type 2 Diabetes: Why Sleep Quality Matters
A good nights sleep can help manage blood sugar, blood pressure, and insulin resistance. Heres how to get high-quality sleep.
Medically Reviewed by Rosalyn Carson-DeWitt, MD
Sign Up for Our Living with Diabetes Newsletter
Sign up for more FREE Everyday Health newsletters .
Most people with type 2 diabetes know that making certain daily lifestyle choices such as eating a healthy diet and getting regular exercise are essential to managing the condition. But what about getting good sleep?
Experts say that quality sleep is just as essential, and that poor sleep negatively affects many health issues related to type 2 diabetes , including blood sugar levels, according to a consensus statement issued by the American Association of Clinical Endocrinologists (AACE) and published in January 2017 in the journal Endocrine Practice .
Poor sleep is very common with type 2 diabetes, says Daniel Einhorn, MD , a clinical endocrinologist, medical director of the Scripps Whittier Diabetes Institute in San Diego, and past president of the AACE. This can have an adverse effect on all aspects of [the condition].
Both the quality and quantity of sleep matter when it comes to type 2 diabetes. According to multiple studies over the past two decades, poor sleep can disrupt a number of factors related to type 2 diabetes, including:
Sleep deprivation affects the bodys ability to use glucose efficiently, which can increase the risk for type 2 diabetes. And people with sleep problems difficulty falling or staying asleep, sleeping fewer than 5 to 6 h Continue reading

No more pages to load

Popular Articles

Related Articles